Retinal ganglion cell complex and visual evoked potentials in levetiracetam treatment.

Autor: Hazirolan D; Ankara Training and Research Hospital, Ophthalmology Department, University of Health Sciences, Ankara, Turkey., Duman M; Ankara City Hospital, Ophthalmology Department, University of Health Sciences, Ankara, Turkey., Guler SK; Ankara Training and Research Hospital, Neurology Department, University of Health Sciences, Ankara, Turkey., Uney G; Ankara Training and Research Hospital, Ophthalmology Department, University of Health Sciences, Ankara, Turkey., Ornek F; Ankara Training and Research Hospital, Ophthalmology Department, University of Health Sciences, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Cutaneous and ocular toxicology [Cutan Ocul Toxicol] 2020 Sep; Vol. 39 (3), pp. 237-243. Date of Electronic Publication: 2020 Jun 26.
DOI: 10.1080/15569527.2020.1778016
Abstrakt: Purpose: To examine central macular, RNFL (retinal nerve fibre layer), GCC (ganglion cell complex) thicknesses; and VEPs (visual evoked potential) in epileptic patients using levetiracetam for at least one year.
Materials and Methods: Sixteen focal epileptic patients receiving levetiracetam monotherapy and 16 healthy subjects were included in the study. Central macular, RNFL and GCC thicknesses according to spectral domain OCT (optical coherence tomography); and VEPs parameters were compared between patients and healthy subjects.
Results: The mean age of patient and control groups were 40 ± 16 and 38 ± 12 years respectively ( p  > 0.05). The patient group was on levetiracetam therapy for 64 ± 45 (12-168) months. Central macular thickness was thinner in the patient group ( p  = 0.008). There was no difference among groups regarding RNFL thicknesses. GCC thicknesses in all quadrants were similar among groups, except the superior quadrant; which was thinner in the patient group ( p  = 0.03). P100 amplitude in 30 min pattern was lower in the patient group ( p  = 0.04). N135 latency in 15 min ( p  = 0.03) and 7 min patterns ( p  = 0.01) was longer in the patient group.
Conclusion: Central macular and GCC thicknesses; and VEP parameters in patients receiving levetiracetam treatment may differ from healthy subjects.
Databáze: MEDLINE
Externí odkaz: